BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 17171788)

  • 1. New multi protein patterns differentiate liver fibrosis stages and hepatocellular carcinoma in chronic hepatitis C serum samples.
    Göbel T; Vorderwülbecke S; Hauck K; Fey H; Häussinger D; Erhardt A
    World J Gastroenterol; 2006 Dec; 12(47):7604-12. PubMed ID: 17171788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease.
    Zinkin NT; Grall F; Bhaskar K; Otu HH; Spentzos D; Kalmowitz B; Wells M; Guerrero M; Asara JM; Libermann TA; Afdhal NH
    Clin Cancer Res; 2008 Jan; 14(2):470-7. PubMed ID: 18223221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surface enhanced laser desorption/ionization profiling: New diagnostic method of HBV-related hepatocellular carcinoma.
    Wu C; Wang Z; Liu L; Zhao P; Wang W; Yao D; Shi B; Lu J; Liao P; Yang Y; Zhu L
    J Gastroenterol Hepatol; 2009 Jan; 24(1):55-62. PubMed ID: 18823443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential proteomic biomarkers in assessing liver fibrosis using SELDI-TOF MS.
    Karatayli SC; Alagöz SG; Mizrak D; Sayki M; Ozkan M; Savaş B; Erden E; Cinar K; Idılman R; Yurdaydin C; Bozdayi AM
    Turk J Gastroenterol; 2012 Feb; 23(1):46-53. PubMed ID: 22505379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SELDI-TOF MS profiling of serum for detection of the progression of chronic hepatitis C to hepatocellular carcinoma.
    Schwegler EE; Cazares L; Steel LF; Adam BL; Johnson DA; Semmes OJ; Block TM; Marrero JA; Drake RR
    Hepatology; 2005 Mar; 41(3):634-42. PubMed ID: 15726646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SELDI-TOF MS proteinchip technology for screening of serum markers of HBV-induced hepatocellular carcinoma.
    Geng X; Wang F; Li YG; Zhu GP; Zhang WM
    J Exp Clin Cancer Res; 2007 Dec; 26(4):505-8. PubMed ID: 18365545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of serum protein fingerprinting coupled with artificial neural network model in diagnosis of hepatocellular carcinoma.
    Wang JX; Zhang B; Yu JK; Liu J; Yang MQ; Zheng S
    Chin Med J (Engl); 2005 Aug; 118(15):1278-84. PubMed ID: 16117882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma lipidomic fingerprinting to distinguish among hepatitis C-related hepatocellular carcinoma, liver cirrhosis, and chronic hepatitis C using MALDI-TOF mass spectrometry: a pilot study.
    Passos-Castilho AM; Lo Turco E; Ferraz ML; Matos C; Silva I; Parise E; Pilau E; Gozzo F; Granato C
    J Gastrointestin Liver Dis; 2015 Mar; 24(1):43-9. PubMed ID: 25822433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of beta2-microgloblin as a candidate for early diagnosis of imaging-invisible hepatocellular carcinoma in patient with liver cirrhosis.
    Saito Y; Oba N; Nishinakagawa S; Mizuguchi Y; Kojima T; Nomura K; Nakatsura T
    Oncol Rep; 2010 May; 23(5):1325-30. PubMed ID: 20372847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential Serum Markers for Monitoring the Progression of Hepatitis B Virus-Associated Chronic Hepatic Lesions to Liver Cirrhosis.
    Wu C; Liu L; Zhao P; Tang D; Yao D; Zhu L; Wang Z
    Gut Liver; 2015 Sep; 9(5):665-71. PubMed ID: 25963079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced detection of early hepatocellular carcinoma by serum SELDI-TOF proteomic signature combined with alpha-fetoprotein marker.
    Chen L; Ho DW; Lee NP; Sun S; Lam B; Wong KF; Yi X; Lau GK; Ng EW; Poon TC; Lai PB; Cai Z; Peng J; Leng X; Poon RT; Luk JM
    Ann Surg Oncol; 2010 Sep; 17(9):2518-25. PubMed ID: 20354800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarker discovery for early detection of hepatocellular carcinoma in hepatitis C-infected patients.
    Mustafa MG; Petersen JR; Ju H; Cicalese L; Snyder N; Haidacher SJ; Denner L; Elferink C
    Mol Cell Proteomics; 2013 Dec; 12(12):3640-52. PubMed ID: 24008390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of chronic hepatitis B, liver cirrhosis and hepatocellular carcinoma by SELDI-based serum decision tree classification.
    Cui J; Kang X; Dai Z; Huang C; Zhou H; Guo K; Li Y; Zhang Y; Sun R; Chen J; Li Y; Tang Z; Uemura T; Liu Y
    J Cancer Res Clin Oncol; 2007 Nov; 133(11):825-34. PubMed ID: 17516088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum peptide pattern that differentially diagnoses hepatitis B virus-related hepatocellular carcinoma from liver cirrhosis.
    Wang N; Cao Y; Song W; He K; Li T; Wang J; Xu B; Si HY; Hu CJ; Li AL
    J Gastroenterol Hepatol; 2014; 29(7):1544-50. PubMed ID: 24612022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibrosis Index Based on 4 Factors (FIB-4) Predicts Liver Cirrhosis and Hepatocellular Carcinoma in Chronic Hepatitis C Virus (HCV) Patients.
    Li X; Xu H; Gao P
    Med Sci Monit; 2019 Sep; 25():7243-7250. PubMed ID: 31558693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early diagnostic potential for hepatocellular carcinoma using the SELDI ProteinChip system.
    Kanmura S; Uto H; Kusumoto K; Ishida Y; Hasuike S; Nagata K; Hayashi K; Ido A; Stuver SO; Tsubouchi H
    Hepatology; 2007 Apr; 45(4):948-56. PubMed ID: 17393466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of complement C3a as a candidate biomarker in human chronic hepatitis C and HCV-related hepatocellular carcinoma using a proteomics approach.
    Lee IN; Chen CH; Sheu JC; Lee HS; Huang GT; Chen DS; Yu CY; Wen CL; Lu FJ; Chow LP
    Proteomics; 2006 May; 6(9):2865-73. PubMed ID: 16586433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum profiling based on fucosylated glycoproteins for differentiating between chronic hepatitis B and hepatocellular carcinoma.
    Liao J; Zhang R; Qian H; Cao L; Zhang Y; Xu W; Li J; Wu M; Yin Z
    Biochem Biophys Res Commun; 2012 Apr; 420(2):308-14. PubMed ID: 22425980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identifying serological biomarkers of hepatocellular carcinoma using surface-enhanced laser desorption/ionization-time-of-flight mass spectroscopy.
    Wu FX; Wang Q; Zhang ZM; Huang S; Yuan WP; Liu JY; Ban KC; Zhao YN
    Cancer Lett; 2009 Jul; 279(2):163-70. PubMed ID: 19268439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of candidate biomarkers for hepatocellular carcinoma in plasma of HCV-infected cirrhotic patients by 2-D DIGE.
    Ferrín G; Ranchal I; Llamoza C; Rodríguez-Perálvarez ML; Romero-Ruiz A; Aguilar-Melero P; López-Cillero P; Briceño J; Muntané J; Montero-Álvarez JL; De la Mata M
    Liver Int; 2014 Mar; 34(3):438-46. PubMed ID: 23944848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.